Brain-accessible peptide reduces stroke damage by targeting TrkB-T1 receptor to modulate neuroinflammation | Research

The takeaway

A brain-accessible peptide targeting the BDNF receptor TrkB-T1 specific interactome modulates the inflammatory response and reduces neurotoxicity in ischemic stroke, offering a new peptide-based approach to neuroprotection.

New stroke neuroprotective peptide
A brain-accessible peptide targeting TrkB-T1 receptor interactome modulates neuroinflammation and neurotoxicity in stroke—a novel approach to brain protection

What the researchers found

Brain-accessible peptide targets TrkB-T1 (truncated BDNF receptor). Modulates: glia reactivity, neuroinflammation, excitotoxicity. TrkB-T1 interactome-specific targeting. Reduces stroke damage. Novel neuroprotective approach.

Why it matters

Stroke has limited treatment options beyond clot removal. A brain-accessible peptide that reduces inflammation and neurotoxicity through a novel target could provide neuroprotection during the critical post-stroke window.

How the study worked

Ischemic stroke models. Brain-accessible peptide design targeting TrkB-T1 interactome. Neuroinflammation and neurotoxicity assessment.

What this study cannot tell us

Preclinical study. Brain accessibility of the peptide needs clinical confirmation. TrkB-T1 interactome complexity. Stroke models may not fully replicate human disease.

How to read the evidence

Preclinical mechanistic study. Novel target and approach.

When this study was published

Published in 2025.

The bigger picture

Targeting specific receptor isoform interactomes rather than the receptor itself is a sophisticated drug design strategy. If successful for stroke, this approach could extend to other neurodegenerative conditions.

Questions still open

What is the peptide's brain penetration mechanism?
Could this combine with tPA for comprehensive stroke treatment?
Does targeting TrkB-T1 affect normal BDNF signaling?

Common questions

Could a peptide treat stroke?

This study developed a peptide that can reach the brain and reduce stroke damage by targeting a specific brain receptor (TrkB-T1). It reduced inflammation and neurotoxicity—the main processes that cause brain damage after a stroke. If confirmed in clinical trials, this could provide a new treatment option during the critical post-stroke window.

How is this different from current stroke treatments?

Current stroke treatment mainly involves removing the blood clot (tPA or thrombectomy). This peptide addresses a different problem: the inflammatory damage that continues after the clot is removed. Combining clot removal with neuroprotective peptide treatment could significantly improve stroke outcomes.

Read the original research

A brain-accessible peptide modulates stroke inflammatory response and neurotoxicity by targeting BDNF-receptor TrkB-T1 specific interactome.

Theranostics, 15(10), 4654-4672

View on PubMed ↗Publisher’s paper ↗

Citation

Ugalde-Triviño, Lola; Tejeda, Gonzalo S; Esteban-Ortega, Gema M; Díaz-Guerra, Margarita. (2025). A brain-accessible peptide modulates stroke inflammatory response and neurotoxicity by targeting BDNF-receptor TrkB-T1 specific interactome.. Theranostics, 15(10), 4654-4672. https://doi.org/10.7150/thno.111272